Market Insights
Pain is a symptom that fundamentally results from any injury, infection, disorder, or disease. Globally, more than 1.5 billion people suffer from different types of pain, and among all, lower back pain, neck pain, headaches, and facial pain are the most common. Unlike acute pain, which is temporary and relieved when the underlying cause is healed, chronic pain, in general, lasts for a longer period of time. Management of pain is accomplished with various treatments, including drug therapy, physical therapy, biofeedback, and others.
The non-opioid pain patch is a kind of treatment for pain relief. The pain patch, when placed on a painful area, releases its medicine content through the skin’s surface and inhibits the transfer of pain signals. The patches can be customized as per the applied area. To counteract opioid abuse, newer, innovative, and more effective non-opioid pain patches are getting developed, which in turn drive the non-opioid pain patch market’s growth.
Rising opioid abuse is a major concern, as only in the U.S., more than 20,000 deaths have been recorded resulting from an opioid overdose. Along with rising opioid abuse, the harmful side effects of opioids drive the usage of non-opioid pain patches and their market. The increasing trend of chronic pain contributes to the growth of the non-opioid pain patch market. The non-opioid pain patch market is still growing, as many of its products are under clinical trial. Teikoku Pharma USA, Inc. declared their recent innovation, a dexmedetomidine transdermal non-opioid pain patch for post-surgical pain treatment, which is still under clinical trial and expected to provide effective results in pain management. However, the lower adoption rate of non-opioid pain patches in contrast to drugs poses some challenges to the growth of the non-opioid pain patch market.
The purpose of this research study titled “Non-Opioid Pain Patch Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” is to provide investors, developers, company executives, and industry participants with in-depth analysis to allow them to take strategic initiatives and decisions related to the prospects in the global non-opioid pain patch market. This report presents and analyses the major trends prevalent in the global non-opioid pain patch market and the market size and forecast.This report categorizes the global non-opioid pain patch market in terms of patch type, distribution channel, and geographical distribution.
On the basis of patch type, the non-opioid pain patch market is classified as follows:
- Lidocaine Patches
- Diclofenac Patches
- Capsaicin Patches
- Methyl Salicylate Patches
- Others
Based on the distribution channel, the non-opioid pain patch market is categorized as follows:
- Hospital pharmacy
- Retail pharmacy or independent pharmacy
- E-commerce/online pharmacy
Each considered geographical market’s market size and forecast are presented for the period 2015-2025, along with CAGRs for the forecast period 2017-2025, and are further cross-sectionally presented in terms of patch type, distribution channel type, and constituent region/country level markets.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global non-opioid pain patch market. Competition assessment tools such as major agreements, partnerships, and collaborations, market attractiveness assessment, and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the non-opioid pain patch market. The key players profiled in this report are The Seng Pharmaceutical Mfg. Co., Ltd., Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd., Allergan, Pfizer, Inc., Hisamitsu Pharmaceutical Co. Inc., GlaxoSmithKline plc., Mylan N.V., IBSA Institut Biochimique SA, Inc., Acorda Therapeutics, and othersTransdermal drug delivery is the best alternative to oral drug delivery. This non-invasive procedure provides a better patient outcome with fewer adverse effects.
Based on the type of patches, the non-opioid pain patch market has been categorized as follows:
- Lidocaine Patches
- Diclofenac Patches
- Capsaicin Patches
- Methyl Salicylate Patches
- Others
A lidocaine patch is a non-opioid that is applied to healthy skin. This patch is used to treat neuropathic pain, generally from post-herpetic neuralgia, and it is also useful for the treatment of diabetic neuropathy or HIV-related neuropathy. Lidoderm was the first Lidocaine patch to receive FDA approval. The lidocaine patch market is expected to be the largest and is estimated to grow more in the near future. The safety, fewer risks, and lesser chances of side effects contribute to the growth of its market.
A methyl salicylate patch is used to treat the pain caused by arthritis, strains, or sprains. Salonpas is the first and only FDA-approved over-the-counter methyl salicylate pain patch. Capsaicin patches help to resolve muscle or joint pains, and Diclofenac patches work by blocking the pain-producing agent for the treatment of pain from minor strains, bruises, or injuries.
Although there are some adverse effects associated with non-opioid patches like allergic reactions, hives, redness, blisters, shortness of breath, etc., the benefits of customization of patches, easy administration, fewer doses, and better patient outcomes contribute to the growth of the non-opioid pain patch market.
Depending on the distribution channel, the non-opioid pain patch market is segmented into the following categories:
- Hospital pharmacy
- Retail pharmacy or independent pharmacy
- E-commerce/Online Pharmacy
The hospital pharmacy is predicted to contribute to the maximum growth of the non-opioid pain patch market, whereas the retail pharmacy and e-commerce are expected to face major growth in the forecasting years due to extensive discounting and easy availability of products. In the case of online pharmacies, the option of free delivery attracts the public’s attention, resulting in expected profitable growth in the coming years.
The global non-opioid pain patch market is divided into five regions: North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America.North America is anticipated to dominate the non-opioid pain patch market, followed by Europe. According to a study by the National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH), more than 50 million people in America suffer from chronic pain. Pain is a serious health issue globally, for which $560–635 billion USD is spent annually on treatment only in the U.S. This rising incidence of severe pain, combined with increased public awareness of health issues, contributes to North America’s dominance. More than 2 million people have substance abuse disorders using prescription opioids, and around 20,000 people died from opioid overdoses in 2015.
This rate of opioid abuse shifts the trend of pain management towards non-opioid patches. Research on innovative and effective product development for pain management drives the non-opioid pain patch market in North America and Europe. The prevalence of post-herpetic neuralgia in the United States is estimated to be around 144,000, and the associated pain is difficult to treat with oral medications, driving increased use of the Lidocaine patch and fueling its growth. The huge number of people suffering from pain disorders, developing healthcare infrastructure, and cost-effectiveness fuel the growth of the non-opioid pain patch market in the Asia-Pacific region, and it is expected to face substantial growth in upcoming periods due to the growing trend of health awareness in public.
The detailed regional classification of the global non-opioid pain patch market is as follows:
- North America (U.S. and Canada)
- Europe (Germany, U.K., France, Spain, Italy, and the Rest of Europe)
- Asia Pacific (China, India, Japan, and the Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and the Rest of Latin America)
- Middle East and Africa (including the Gulf Cooperation Council and the rest of the Middle East and Africa)
